- Home
- GMAB
GMAB
Genmab A/S ADS
as 11-20-2024 4:00pm EST
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.0B | IPO Year: | N/A |
| Target Price: | $43.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.80 | EPS Growth: | 14.35 |
| 52 Week Low/High: | $20.37 - $32.88 | Next Earning Date: | 11-06-2024 |
| Revenue: | $2,967,926,227 | Revenue Growth: | 17.75% |
| Revenue Growth (this year): | 30.31% | Revenue Growth (next year): | 16.49% |
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
Simply Wall St.
13 days ago
High Growth Tech Stocks To Watch In November 2024
GuruFocus.com
14 days ago
Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...
MT Newswires
15 days ago
Genmab Shares Fall After Reporting Q3 Results
GlobeNewswire
15 days ago
Genmab Announces Financial Results for the First Nine Months of 2024
GlobeNewswire
16 days ago
Genmab to Present at Jefferies London Healthcare Conference
Business Wire
16 days ago
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
Insider Monkey
a month ago
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
Compare GMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.